Drug intelligence / Profile preview

BPP-1001

Development stage: Preclinical
Lead developer: Bioscience Pharma Partners
Modality: Small Molecules
Administration: Intravenous

Overview

BPP-1001 is an investigational **small-molecule** inhibitor of **5-lipoxygenase-activating protein** intended to modulate leukotriene biosynthesis and related inflammatory signaling pathways. It has been described as being developed by **Bioscience Pharma Partners** and, based on the provided context, remains at the **discovery** stage with a stated focus in **nervous system** disorders. Publicly available detail appears limited, and no specific clinical-stage indication, formulation, or route of administration is clearly established from the supplied evidence.

Targets

FLAP (Arachidonate 5-lipoxygenase-activating protein)

Beyond the preview

Go deeper on BPP-1001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BPP-1001.

Explore the full profile